drugset / Trial / NCT06182735
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, single-arm study conducted to evaluate the safety, tolerability, PK, and preliminary efficacy of CGC729 with Relapsed or Metastatic advanced renal cell carcinoma. Condition or disease:Renal Cell Carcinoma Intervention/treatment: Biological: CD70 CAR-NKT cells Phase 1
Timeline
- Start
- 2023-07-17
- Primary completion
- 2025-01-28
- Completion
- 2025-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CGC729 | Cell therapy | 1.5 unknown | — |
| Subject | CGC729 | Cell therapy | 4.5 unknown | — |
| Subject | CGC729 | Cell therapy | 5 unknown | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |